← Back to patent-cliff list
NBI-1117567
Tier C — Watch / tradeNBI-1117567
Nxera Pharma Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CHRM1
Indications (approved)：Alzheimer's disease, 中枢神经系统紊乱, 精神疾病, 神经疾病
Regional status
US
Phase I
2026-03-01
EU
-
China
-
Japan
-
2023-12-06
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NBI-1117567?
Approved indications include: Alzheimer's disease, 中枢神经系统紊乱, 精神疾病, 神经疾病.
When does the NBI-1117567 patent expire?
No public expiry year is available for NBI-1117567 yet; this page updates once verified.
How do I get a quote for NBI-1117567 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-28